Clinical Trial Partnerships Curtana's multi-site Phase 1 OPAL trial for CT-179 in recurrent glioblastoma in Australia, run with COGNO and ABCARA, signals demand for CRO services, trial management, regulatory consulting, site networks, and imaging/biomarker support.

Advocacy Recruitment Recent partnerships with Brain Cancer Australia Charity and COGNO indicate openness to advocacy-driven recruitment channels, patient access programs, and fundraising partnerships that can accelerate enrollment and widen trial awareness.

CNS Oncology Focus Curtana's focus on cancer stem cells in the CNS with first-in-class small molecules positions it for strategic licensing, co-development, or technology partnerships with larger pharma seeking CNS oncology assets.

Manufacturing and Supply As a preclinical-stage biotech moving toward Phase 1, Curtana will need GMP manufacturing, formulation development, analytical services, and supply chain partners for clinical materials.

Strategic Financing With modest funding alongside growing revenue, Curtana represents a potential target for early-stage to mid-tier pharma investors, licensing deals, or strategic partnerships to de-risk development.